31085-56-0

Basic information

• Product Name: N-(Triphenylmethyl)-2'-O,5'-O-bis(triphenylmethyl)adenosine
• Synonyms: N-(Triphenylmethyl)-2'-O,5'-O-bis(triphenylmethyl)adenosine;N,2'-O,5'-O-Tris(triphenylmethyl)adenosine
• CAS NO: 31085-56-0
• Molecular Formula: C₆₇H₅₅N₅O₄
• Molecular Weight: 994.18
• Mol File: 31085-56-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(Triphenylmethyl)-2'-O,5'-O-bis(triphenylmethyl)adenosine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(Triphenylmethyl)-2'-O,5'-O-bis(triphenylmethyl)adenosine(31085-56-0)
• EPA Substance Registry System: N-(Triphenylmethyl)-2'-O,5'-O-bis(triphenylmethyl)adenosine(31085-56-0)

Safety Data

• Hazardous Substances Data: 31085-56-0(Hazardous Substances Data)

Upstream product

• 69304-45-6 3',5'-O-(1,1,3,3-tetra-isopropyldisiloxane-1,3-diyl)adenosine 
• 58-61-7 adenosine 
• 76-83-5 trityl chloride 
• 137965-10-7 (2R,3R,4R,5R)-2-(hydroxymethyl)-5-(6-(tritylamino)-9H-purin-9-yl)-4-(trityloxy)tetra-hydrofuran-3-ol 

Downstream Products

• 191853-42-6 6-{(2R,3R,4R,5R)-5-[6-(Trityl-amino)-purin-9-yl]-4-trityloxy-2-trityloxymethyl-tetrahydro-furan-3-yloxy}-hexanoic acid ethyl ester 
• 191853-38-0 {9-[(2R,3R,4R,5R)-4-(2-{2-[Dimethyl-(1,1,2-trimethyl-propyl)-silanyloxy]-ethoxy}-ethoxy)-3-trityloxy-5-trityloxymethyl-tetrahydro-furan-2-yl]-9H-purin-6-yl}-trityl-amine 
• 191853-36-8 [9-((2R,3R,4R,5R)-4-{11-[Dimethyl-(1,1,2-trimethyl-propyl)-silanyloxy]-undecyloxy}-3-trityloxy-5-trityloxymethyl-tetrahydro-furan-2-yl)-9H-purin-6-yl]-trityl-amine 
• 191853-37-9 [9-((2R,3R,4R,5R)-4-{12-[Dimethyl-(1,1,2-trimethyl-propyl)-silanyloxy]-dodecyloxy}-3-trityloxy-5-trityloxymethyl-tetrahydro-furan-2-yl)-9H-purin-6-yl]-trityl-amine 
• 121409-47-0 9-(2,5-Di-O-trityl-3-deoxy-3-fluoro-β-D-ribofuranosyl)-6-trityladenine 
• 137965-14-1 9-(3,5-Di-O-benzyl-β-D-arabinofuranosyl)adenine 
• 137965-12-9 3',5'-Di-O-benzyladenosine 
• 137965-11-8 3',5'-Di-O-benzyl-2'-O-trityl-N⁶-trityladenosine 
• 137965-13-0 9-(3,5-Di-O-benzyl-2-O-triflyl-β-D-ribofuranosyl)adenine 
• 137965-15-2 2'-Deoxy-2'-fluoro-3',5'-di-O-benzyladenosine 
• 121409-46-9 9-(2,5-Di-O-trityl-β-D-xylofuranosyl)-6-trityladenine 
• 191853-48-2 6-{(2R,3R,4R,5R)-5-[6-(Trityl-amino)-purin-9-yl]-4-trityloxy-2-trityloxymethyl-tetrahydro-furan-3-yloxy}-hexanoic acid 9H-fluoren-9-ylmethyl ester 
• 191853-64-2 6-{(2R,3R,4R,5R)-2-[(4-Methoxy-phenyl)-diphenyl-methoxymethyl]-5-{6-[2-(4-nitro-phenyl)-ethoxycarbonylamino]-purin-9-yl}-4-[2-(4-nitro-phenyl)-ethoxycarbonyloxy]-tetrahydro-furan-3-yloxy}-hexanoic acid 2-cyano-ethyl ester 
• 191853-47-1 6-{(2R,3R,4R,5R)-5-[6-(Trityl-amino)-purin-9-yl]-4-trityloxy-2-trityloxymethyl-tetrahydro-furan-3-yloxy}-hexanoic acid 2-cyano-ethyl ester 

Relevant articles and documents

LOCKED NUCLEIC ACID CYCLIC DINUCLEOTIDE COMPOUNDS AND USES THEREOF

The present invention provides highly active locked nucleic acid cyclic-dinucleotide (LNA-CDN) immune stimulators that activate DCs via the cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the LNA-CDNs of the present in

COMPOSITIONS AND METHODS FOR ACTIVATING "STIMULATOR OF INTERFERON GENE"-DEPENDENT SIGNALLING

The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinuclotides present in the composition are 2'- or 3'-mono-fluoro substituted, or 2'3'-di-fluoro substituted mixed linkage 2',5' - 3',5' CDNs.

Synthesis of 3′-fluoro-trna analogues for exploring nonribosomal peptide synthesis in bacteria

Aminoacyl-tRNAs (aa-tRNAs) participate in a vast repertoire of metabolic pathways, including the synthesis of the peptidoglycan network in the cell walls of bacterial pathogens. Synthesis of aminoacyl-tRNA analogues is critical for further understanding the mechanisms of these reactions. Here we report the semi-synthesis of 3′-fluoro analogues of Ala-tRNAAla. The presence of fluorine in the 3′-position blocks Ala at the 2′-position by preventing spontaneous migration of the residue between positions 2′ and 3′. NMR analyses showed that substitution of the 3′-hydroxy group by fluorine in the ribo configuration favours the S-type conformation of the furanose ring of terminal adenosine A76. In contrast, the N-type conformation is favoured by the presence of fluorine in the xylo configuration. Thus, introduction of fluorine in the ribo and xylo configurations affects the conformation of the furanose ring in reciprocal ways. These compounds should provide insight into substrate recognition by Fem transferases and the Ala-tRNA synthetases.